Production of active pharmaceutical substances. After reaching the design capacity the company will be able to cover Russian needs in insulin for 100 % and to expand export opportunities

A leading full-cycle producer of gene-engineering human insulin – from synthesis of a substance to finished dosage form. The plant can cover 30 % of Russian needs in insulin